Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer is a research paper published in BMJ Oncology (2024). On theSindex it has a DataRank of 0.473. It has been cited 13 times, with 13 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.396
From this paper's citation signal
Citation Network Contribution
0.0773
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 13 citers.
Clinical Center
Grant: P30 CA016672
AstraZeneca
Grant: N/A
FWCI
2.26
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals